摘要
目的:探讨影响甲状腺髓样癌(medullary thyroid carcinoma,MTC)患者生存的预后因素。方法:纳入1995年1月1日至2015年12月31日在云南省肿瘤医院及中山大学肿瘤防治中心接受治疗的MTC患者,回顾性分析其临床资料和随访资料。结果:123例MTC患者的5年、10年总生存率分别为91.6%、77.9%,单因素分析发现患者就诊时年龄、性别、术前血清降钙素水平、原发灶大小、有无局部浸润、确诊时cTNM分期、远处转移、是否接受手术影响患者预后。多因素分析提示患者就诊时年龄、性别、原发灶大小、确诊时cTNM分期、远处转移和是否接受手术治疗是MTC患者预后的独立影响因素。结论:MTC患者确诊时年龄<40岁较≥40岁的预后好,男性、血清降钙素水平≥1000pg/mL、原发灶>4cm、cTNM分期为Ⅳ期、有远处转移的患者预后较差,手术治疗有助于改善MTC患者预后。
Objective: To investigate prognostic factors for patients with medullary thyroid carcinoma(MTC). Methods:Clinical information and follow-up data of 123 patients with MTC treated in Yunnan Cancer Hospital and Sun Yat-sen University Cancer Center between January 1,1995 and December 31,2015 were retrospectively analyzed with respect to mortality and survival rates by using Kaplan-Meier survival analysis and Cox regression model. Results: The 5-year,10-year and 15-year overall survival rates were 91. 6%, 77. 9% and 63. 4% %,respectively,for all patients. Univariate analysis showed that age,sex,preoperative serum calcitonin level,primary tumor size,local infiltration,cTNM stage,distant metastasis and surgery affected prognosis of patients. Cox regression analysis showed that age,gender,primary tumor size,cTNM stage,distant metastasis and receiving surgery were independent prognostic factors for MTC patients. Conclusion: MTC patients aged < 40 years had a better prognosis compared to those aged ≥40 years. Male,preoperative serum calcitonin level ≥1000 pg/mL,primary tumor size > 4 cm,local infiltration,cTNM stage and distant metastasis were factors of unfavorable prognosis for patients with MTC. However,surgical treatment can significantly improve the prognosis of patients with MTC.
作者
王士琪
储红映
赵再礼
钟兆铭
秦汝佳
王学敏
齐潇
杨安奎
孙传政
Wang Shiqi;Chu Hongying;Zhao Zaili;Zhong Zhaoming;Qin Rujia;Wang Xuemin;Qi Xiao;Yang Ankui;Sun Chuanzheng(SectionⅡ,Department of Head and Neck Surgery,Yunnan Cancer Hospital&The Third Affiliated Hospital of Kunming Medical University&Yunnan Cancer Center,Kunming 650118,China;Department of Head and Neck,Sun Yat-sen University Cancer Center,Guangzhou 510060,Guangdong,China)
出处
《肿瘤预防与治疗》
2019年第12期1099-1105,共7页
Journal of Cancer Control And Treatment
基金
国家自然科学基金(编号:81560470,81773127)
云南省中青年学术技术带头人后备人才专项经费(编号:2015HB086)
云南省医学领军人才专项经费(编号:L-2017)~~
关键词
甲状腺髓样癌
血清降钙素
预后
Medullary thyroid carcinoma
Serum calcitonin
Prognosis
